Relapsing‑Remitting Multiple Sclerosis (RRMS)
Overview
Relapsing‑remitting multiple sclerosis (RRMS) is the most common disease‑course of multiple sclerosis (MS), a chronic, immune‑mediated disorder that damages the protective myelin sheath surrounding nerve fibers in the central nervous system (CNS). In RRMS, patients experience clearly defined attacks (relapses or exacerbations) of neurological dysfunction followed by periods of partial or complete recovery (remission). Over time, many individuals transition to a secondary progressive form, but early identification and treatment can markedly slow that progression.
Who is affected? MS usually begins between ages 20‑40, and RRMS accounts for approximately 85 % of initial diagnoses. Women are about three times more likely than men to develop RRMS.[1]
Prevalence and incidence (2023 data):
- Worldwide prevalence: ~ 2.8 million people have MS; RRMS represents roughly 2.4 million of those cases.[2]
- United States: ~ 1 million adults live with MS; ~ 850,000 have RRMS.[3]
- Incidence varies geographically, with higher rates in northern Europe, North America, and parts of Australia (up to 10 per 100,000 per year).[4]
Symptoms
Symptoms of RRMS arise during relapses when inflammation damages myelin and sometimes axons. The pattern, severity, and combination of symptoms differ dramatically between individuals.
Common neurological symptoms
- Visual disturbances – blurred vision, pain with eye movement, or partial loss of vision (optic neuritis).
- Motor weakness – loss of strength in one or more limbs, often unilateral.
- Numbness or tingling – “pins and needles” sensation, commonly in the face, arms, or legs.
- Spasticity – involuntary muscle stiffness or jerking movements.
- Coordination problems (ataxia) – clumsiness, difficulty walking or performing fine motor tasks.
- Balance & gait instability – stumbling, veering to one side.
- Fatigue – overwhelming tiredness that is not improved by rest; reported by >80 % of patients.
- Pain – neuropathic pain (burning, electric‑shock sensations) and musculoskeletal pain from spasticity.
- Cognitive changes – slowed processing speed, memory lapses, difficulties with attention.
- Bladder & bowel dysfunction – urgency, frequency, retention, or constipation.
- Sexual dysfunction – decreased libido, erectile dysfunction, or vaginal dryness.
Less common or atypical manifestations
- Speech difficulty (dysarthria) or swallowing problems (dysphagia).
- Heat sensitivity (Uhthoff’s phenomenon) – temporary worsening of symptoms in hot environments.
- Depression, anxiety, or mood swings – emotional changes are frequent due to both disease and psychosocial impact.
Causes and Risk Factors
RRMS is not caused by a single factor. It results from a complex interplay of genetic susceptibility, abnormal immune responses, and environmental triggers.
Genetic factors
- Having a first‑degree relative with MS increases risk 20‑40 fold, though identical twins are concordant only ~30 % of the time, indicating non‑genetic elements are essential.[5]
- Specific HLA‑DRB1*15:01 allele and other immune‑related genes are consistently associated with higher susceptibility.
Environmental and lifestyle factors
- Vitamin D deficiency – low serum 25‑OH‑vitamin D levels correlate with higher MS risk; residing at higher latitudes (less sunlight) is a known risk factor.[6]
- Epstein‑Barr virus (EBV) infection – a history of infectious mononucleosis or seropositivity for EBV antibodies dramatically raises risk (estimated OR ≈ 8‑10).[7]
- Smoking – current smokers have a 1.5‑2 × greater risk and faster progression.[8]
- Obesity in adolescence – BMI ≥ 30 kg/m² before age 20 associated with increased risk, especially in females.[9]
- Other possible contributors: high‑salt diet, gut microbiome alterations, exposure to certain solvents, and chronic stress (data still emerging).
Diagnosis
Diagnosing RRMS relies on a combination of clinical assessment, magnetic resonance imaging (MRI), and laboratory tests to demonstrate dissemination of lesions in time and space.
Clinical criteria
- McDonald Criteria (2017 revision) – the current gold standard. Requires ≥2 attacks and ≥2 separate CNS regions, or one attack with MRI evidence of multiple lesions.
Imaging studies
- MRI of brain and spinal cord – T2‑weighted and FLAIR sequences show hyperintense plaques; gadolinium‑enhanced T1 images identify active inflammation.
- Optic nerve imaging (orbital MRI) – useful for confirming optic neuritis.
Laboratory & ancillary tests
- Cerebrospinal fluid (CSF) analysis – oligoclonal bands (IgG) present in ~85 % of RRMS patients.
- Serum tests – EBV, vitamin D level, and infectious work‑up to exclude mimics (e.g., Lyme disease, neuromyelitis optica).
- Evoked potentials – visual, auditory, or somatosensory studies can reveal subclinical lesions.
Exclusion of other conditions
Conditions that can mimic RRMS include neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), systemic lupus erythematosus, and vascular lesions. Careful history, antibody testing (e.g., anti‑AQP4, anti‑MOG), and imaging help differentiate them.
Treatment Options
Therapy for RRMS focuses on three goals: (1) modify the disease course, (2) treat acute relapses, and (3) manage symptoms.
Disease‑Modifying Therapies (DMTs)
All FDA‑approved DMTs for RRMS aim to reduce relapse frequency and MRI activity.
- Injectables
- Interferon‑β‑1a (Avonex, Rebif) – weekly or three times weekly injections.
- Interferon‑β‑1b (Betaseron, Extavia) – every other day.
- Glatiramer acetate (Copaxone, Glatopa) – daily or three times weekly.
- Oral agents
- Fingolimod (Gilenya) – sphingosine‑1‑phosphate receptor modulator; requires cardiac monitoring first dose.
- Dimethyl fumarate (Tecfidera) – anti‑inflammatory; monitor lymphocyte counts.
- Teriflunomide (Aubagio) – inhibits pyrimidine synthesis; contraindicated in pregnancy.
- Cladribine (Mavenclad) – short‑course oral immunosuppressant; watch for lymphopenia.
- Ponesimod (Ponvory) – newer S1P modulator with once‑daily dosing.
- Infusions
- Natalizumab (Tysabri) – anti‑α4 integrin; risk of progressive multifocal leukoencephalopathy (PML) – requires JC virus antibody monitoring.
- Ocrelizumab (Ocrevus) – anti‑CD20 B‑cell depleting; infusions every 6 months; screen for hepatitis B.
- Alemtuzumab (Lemtrada) – anti‑CD52; high efficacy but notable autoimmune adverse events, requiring long‑term labs.
Choice of DMT is individualized based on disease activity, comorbidities, reproductive plans, and patient preference.
Treating Acute Relapses
- Corticosteroids – high‑dose IV methylprednisolone 500‑1000 mg/day for 3‑5 days, often followed by an oral taper.
- Plasma exchange (PLEX) – considered for severe relapses unresponsive to steroids, especially in optic neuritis or transverse myelitis.
Symptom‑Targeted Therapies
- Spasticity – baclofen, tizanidine, or gabapentin; physical therapy.
- Fatigue – amantadine, modafinil, or scheduled energy‑conservation strategies.
- Pain – neuropathic agents (duloxetine, pregabalin) and topical lidocaine.
- Bladder – anticholinergics (oxybutynin) or intermittent catheterization.
- Depression/anxiety – SSRIs, counseling, or cognitive‑behavioral therapy.
Lifestyle & Adjunct Measures
- Vitamin D supplementation (≥ 1000–2000 IU/day) if serum 25‑OH‑D <30 ng/mL.
- Regular moderate exercise (aerobic + resistance) improves strength and fatigue.
- Smoking cessation and weight management.
- Vaccinations – annual flu, COVID‑19, and pneumococcal as recommended; avoid live vaccines while on most DMTs.
Living with Relapsing‑Remitting Multiple Sclerosis
RRMS is a lifelong condition, but most people lead active, productive lives with proper management.
Daily management tips
- Medication adherence – set alarms, use pill organizers, and keep a medication diary.
- Track relapses – note new symptoms, duration, triggers, and share with your neurologist.
- Energy conservation – prioritize tasks, schedule rest periods, and use assistive devices (e.g., walking poles).
- Exercise routine – aim for 150 minutes of moderate cardio weekly; incorporate yoga or tai‑chi for balance.
- Heat management – cool showers, air‑conditioned environments, and cooling vests can reduce Uhthoff’s phenomenon.
- Nutrition – Mediterranean‑style diet rich in omega‑3 fatty acids, fruits, vegetables, and whole grains supports overall health.
- Psychosocial support – join MS support groups, seek counseling, and consider cognitive rehabilitation if needed.
- Regular follow‑up – MRI every 6‑12 months (or as directed) and routine labs for DMT safety.
Work and education
Most individuals with RRMS can continue employment or studies with reasonable accommodations (flexible hours, ergonomic workstations, remote work options). The Social Security Administration provides disability benefits for those whose disease progresses.
Family planning
Pregnancy is generally safe for women with RRMS, and relapse rates often decline during pregnancy but may increase postpartum. Discuss DMT cessation or switching with a neurologist well before conception. Breastfeeding decisions should also consider medication safety.
Prevention
Because RRMS cannot be completely prevented, the focus is on reducing modifiable risk factors.
- Maintain adequate vitamin D levels through sunlight exposure, diet, or supplementation.
- Adopt a non‑smoking lifestyle; use cessation programs if needed.
- Maintain a healthy weight during adolescence and adulthood.
- Practice good hygiene to limit EBV infection severity; research is ongoing into EBV vaccines.
- Engage in regular physical activity, which may have immunomodulatory effects.
Complications
If RRMS is untreated or poorly controlled, several long‑term complications can develop:
- Progressive disability – accumulation of irreversible neurologic deficits leading to wheelchair dependence.
- Cognitive decline – affecting employment and daily decision‑making.
- Urologic complications – recurrent urinary tract infections, renal impairment.
- Secondary progressive MS – transition to a phase with steady worsening and fewer relapses.
- Psychiatric disorders – major depression, anxiety, and increased suicide risk.
- Bone health issues – reduced mobility and steroid use increase osteoporosis risk.
- Infection risk – especially with high‑efficacy immunosuppressive DMTs (e.g., PML, opportunistic infections).
When to Seek Emergency Care
- Sudden, severe weakness or loss of vision in one eye.
- Acute onset of numbness or tingling that spreads rapidly (e.g., progresses over minutes to hours).
- Difficulty breathing, swallowing, or speaking.
- Severe, unrelenting pain that does not respond to usual medications.
- New or worsening bladder/bowel incontinence accompanied by fever (possible infection).
- Signs of a serious infection while on a disease‑modifying therapy: high fever, chills, persistent cough, or severe headache.
Prompt treatment can prevent permanent neurologic damage.
References
- National Multiple Sclerosis Society. “Who Gets MS?” 2023. https://www.nationalmssociety.org
- World Health Organization. “Global Atlas of Multiple Sclerosis, 2022.” https://www.who.int
- Mayo Clinic. “Multiple sclerosis prevalence in the United States.” 2023. https://www.mayoclinic.org
- International Multiple Sclerosis Genetics Consortium. “Geographic variation in MS incidence.” *Lancet Neurology*, 2021.
- Harbor, J. et al. “Genetic susceptibility to multiple sclerosis.” *Nature Reviews Neurology*, 2022.
- Simpson, S., et al. “Vitamin D and risk of multiple sclerosis: a systematic review.” *Neurology*, 2020.
- Hand, D. et al. “EBV infection as a trigger for MS.” *Science Translational Medicine*, 2022.
- Singer, C., et al. “Smoking and multiple sclerosis progression.” *JAMA Neurology*, 2021.
- Koch, H. et al. “Adolescent obesity and risk of MS.” *Annals of Neurology*, 2020.